November 27, 2019New England Journal of Medicine
Essential Thrombocythemia
Authors
Discussion
Loading...
Member takes
Implication
Clinical review outlines thrombosis risk factors and management strategies in essential thrombocythemia, highlighting risk-adapted therapy.
Key Points
- To review the evaluation of vascular complication risks and management strategies for patients with essential thrombocythemia.
- Assessed clinical risk factors for vascular events, including age, prior thrombotic events, cardiovascular risk factors, and genetic markers.
- Evaluated therapeutic approaches based on patient thrombotic risk stratification.
- Essential thrombocythemia elevates individual risks for both abnormal bleeding and dangerous blood clot formation.
- Thrombosis risk estimation relies on patient age, prior thrombosis history, presence of the JAK2 V617F mutation, and cardiovascular risk factors.
- Management routinely incorporates low-dose aspirin, with cytoreductive therapy reserved for patients stratified into high thrombotic risk categories.
Cite This Study
Tefferi et al. (2019) studied this question.